Bucolome in prevention of hyperbilirubinaemia in preterm infants.

Fifty preterm babies were randomly assigned to a group given oral bucolome (30 mg/kg per day for 5 days) and a control group. Serum bilirubin levels of the treated infants from day 4 onwards were consistently lower than those of the control infants. 3 of the 25 control infants (but none of the 25 treated infants) had bilirubin levels greater than 18 mg/100 ml (308 mumol/l) and required exchange transfusion. No sedation or drowsiness was observed in the infants given bucolome, and though the drug caused some vomiting, weight gains were unaffected.     

Phototherapy for hyperbilirubinaemia in very low birthweight infants.

Phototherapy was used to treat 20 newborn babies whose birthweight was below 1500 g and whose plasma bilirubin exceeded 8 mg/100 ml. The plasma bilirubin level was maintained below 13 mg/100 ml except in 4 babies whose level exceeded 13 mg/100 ml before treatment was started. In 60% of an untreated group of larger babies previously reported the plasma bilirubin level exceeded this figure. Phototherapy seems to control the plasma bilirubin level satisfactorily in very low birthweight infants, but frequent measurements on the second and third days of life are advised in order that treatment may be started promptly when it exceeds 8 mg/100 ml.     

Phototherapy for hyperbilirubinaemia in low birthweight infants

Eighty-eight babies whose birthweights were between 1500 g and 2500 g, and whose serum bilirubin reached 10 mg/100 ml, were entered into a controlled trial of phototherapy. Alternate babies were treated with 4000 to 5000 lux, and control cases were not treated unless the bilirubin exceeded 15 mg/100 ml. No baby in the treated group developed a serum bilirubin greater than 15 mg/100 ml, compared with 44% of untreated cases, a highly significant difference. No side effects occurred apart from overheating in a few babies. We conclude that phototherapy is a safe and effective way of treating hyperbilirubinaemia in low birthweight infants, and suggest it should be started when the bilirubin reaches 12 mg/100 ml, except for babies under 1500 g birthweight when it should be started at 10 mg/100 ml.     

Beta glucuronidase and hyperbilirubinaemia in breast fed infants of diabetic mothers.

A prospective study was performed comparing bilirubin concentrations in 10 breast fed term infants of diabetic mothers (IDM) to those of 10 breast fed normal term infants. The beta-glucuronidase concentrations in serum and breast milk were assayed in the respective mothers. Significantly higher bilirubin concentrations were noted in the IDM group. Serum and breast milk beta-glucuronidase concentrations were significantly higher in diabetic mothers as compared with those of non-diabetic mothers. We suggest that the high concentration of beta-glucuronidase in breast milk of diabetic mothers is an additional important cause leading to hyperbilirubinaemia in their breast fed infants.     

Phototherapy for hyperbilirubinaemia in very low birthweight infants

Phototherapy was used to treat 20 newborn babies whose birthweight was below 1500 g and whose plasma bilirubin exceeded 8 mg/100 ml. The plasma bilirubin level was maintained below 13 mg/100 ml except in 4 babies whose level exceeded 13 mg/100 ml before treatment was started. In 60% of an untreated group of larger babies previously reported the plasma bilirubin level exceeded this figure. Phototherapy seems to control the plasma bilirubin level satisfactorily in very low birthweight infants, but frequent measurements on the second and third days of life are advised in order that treatment may be started promptly when it exceeds 8 mg/100 ml.     

Efficacy of phototherapy for hyperbilirubinaemia in infants with the respiratory distress syndrome

Objectives: To evaluate the efficacy of phototherapy for hyperbilirubinaemia in preterm infants with and without the respiratory distress syndrome (RDS).
Methodology: Prospective cohort study of preterm infants cared for at Kandang Kerbau Hospital, Singapore: 170 with RDS and 477 without RDS, sepsis or other complications (control group) presenting with non-haemolytic hyperbilirubinaemia at about the same time were exposed to daylight phototherapy when bilirubin concentrations exceeded 255 μmol/L or 222 μmol/L if <48h of age. Bilirubin values were monitored 6-hourly during exposure, and daily for at least 2 days postphototherapy.
Results The infants were comparable in birthweight, gestational age, postnatal age, haemoglobin, haematocrit and bilirubin values, at start. The response to phototherapy of the infants with RDS was comparable to that of the well preterm infants; the duration of exposure was 50.1 ± 1.6 (mean ± s.e.m.) versus 50.1 ± 1.4 h, 24-hour decline rate 25.71 ± 1.29% versus 26.32 ± 0.65, and overall decline rate 0.96± 0.03%/h versus 0.95±0.02%/h.
Conclusion The presence of RDS did not affect the efficacy of phototherapy for neonatal hyperbilirubinaemia in preterm infants.     

Extreme hyperbilirubinaemia in term and near-term infants in Denmark

AIM: To determine the incidence amongst infants born at term or near-term of extreme hyperbilirubinaemia, i.e., with a serum concentration of unconjugated bilirubin exceeding the limit above which an exchange transfusion was indicated according to the authorized guidelines. METHOD: The investigation period covered 2 y, 1 January 2000 to 31 December 2001, and included all infants born alive at term or near-term in Denmark. All infants with extreme hyperbilirubinaemia admitted to paediatric departments were recorded. RESULTS: Thirty-two infants developed extreme hyperbilirubinaemia, i.e., an incidence of 25 per 100 000. The maximum total serum bilirubin concentration (TSB) was 492 (385-689) micromol/I (median (range)). The median value of the exchange transfusion limits was 450 micromol/l. Twelve infants had signs and symptoms of central nervous system involvement; 11 had acute bilirubin encephalopathy phase-1 symptoms; and one had phase-2 symptoms. Nineteen infants developed extreme hyperbilirubinaemia during primary admission to the maternity ward or neonatal department; the others after having been discharged. There was no difference in maximum TSB between those infants not discharged from hospital and those infants admitted to hospital from home. Maximum TSB appeared latest amongst those infants admitted from home (p < 0.01), and these more often had signs and symptoms of central nervous system involvement (p < 0.05). Ten infants were of non-Caucasian extraction. Less than half of all Danish mothers receive both verbal and written information after birth on jaundice in the infant. CONCLUSION: Twenty-five per 100 000 infants born at term or near-term developed extreme hyperbilirubinaemia, the majority of them whilst in hospital. Infants admitted from home more often had signs and symptoms of central system involvement.     

Surveillance of extreme hyperbilirubinaemia in Denmark. A method to identify the newborn infants

AIM: To describe the incidence of infants born at term or near-term with extreme hyperbilirubinaemia. METHODS: The study period was between 1 January 2002 and 31 December 2005, and included all infants born alive at term or near-term in Denmark. Medical reports on all newborn infants with a total serum bilirubin concentration (TSB) > or = 450 micromol/L were obtained by linking laboratory data to the unique Danish personal identification number. RESULTS: In total, 113 infants were included, that is, an incidence of 45/100,000 live births. Thirty-seven infants presented in hospital, 2 after home birth and the others after having been discharged. The maximum TSB was 485 (450-734) micromol/L (median [range]) and appeared latest amongst those infants admitted from home, but was not different from the maximum TSB of the nondischarged infants. Forty-three infants had symptoms of early-phase acute bilirubin encephalopathy; one infant had advanced-phase symptoms. Four infants received an exchange transfusion. ABO blood group incompatibility was present in 52 infants. Thirty-seven infants were of non-Caucasian descent. CONCLUSION: A method to obtain the national epidemiological data is presented. The observed incidence of extreme hyperbilirubinaemia is higher than previously reported in Denmark. This is mainly due to a very sensitive method of identifying the study group.     

Fibre optic versus conventional phototherapy for hyperbilirubinaemia in preterm infants

Studies comparing efficacy of fibre optic phototherapy to conventional phototherapy are performed mostly in term infants and give conflicting results. This randomized prospective study compares efficacy of fibre optic phototherapy using the Ohmeda Biliblanket device to conventional fluorescent phototherapy in preterm infants. A total of 124 preterm infants with a nonhaemolytic hyperbilirubinaemia were evaluated. Stratification at randomisation was performed according to birth weight (<1000 g, 1000–1500 g or 1500–2000 g). Fifty-six infants received fibre optic and 68 conventional phototherapy. Efficacy was assessed by comparing the required duration of phototherapy. Median duration of phototherapy was 118 h and 114 h in the fibre optic and conventional groups respectively, the difference in which was not statistically significant. The median durations were also not significantly different within the separate weight groups. The number of infants requiring exchange transfusions was similar in both treatment groups. Conclusion The efficacy of fibre optic phototherapy in preterm infants is comparable to conventional phototherapy. Received: 14 May 1996 and in revised form: 20 June 1997 / Accepted: 23 June 1997     

Abnormal results of biochemical liver function tests in breast-fed infants with prolonged indirect hyperbilirubinaemia

To clarify the relationship between hyperbilirubinaemia and abnormal results of biochemical liver function tests in infants with breast milk jaundice (BMJ), 58 breast-fed infants with indirect hyperbilirubinaemia were enrolled in this study. Sera obtained from the above infants were subjected to routine liver function tests. Although serum transaminases were within normal limits in all 58 patients, serum alkaline phosphatase levels were abnormally increased in 13, gamma-glutamyltranspeptidase in 8 and total bile acids in 11 out of all patients examined. A total of 18 (31%) patients had abnormal results in at least one item of the liver function tests. The intrinsic bile acid loading test showed postprandial increases in bile acids in 5 of 16 (31%) patients examined at either 60 or 120 min, while all 13 breast-fed, agematched controls had no abnormal results. The decrease in rate of serum bilirubin levels after the 3-day discontinuation of breast-feeding was significantly less in patients with increased fasting bile acids than in patients with normal fasting levels of serum bile acids. These results may suggest that mild hepatic dysfunction or cholestasis is associated with indirect hyperbilirubinaemia in some infants with BMJ.     

Current Italian practices regarding the management of hyperbilirubinaemia in preterm infants

Aim: To assess the current practices existing in Italy for the management of jaundice in preterm infants as preliminary achievement to a call for national guidelines and establishment of a kernicterus registry. Methods: A questionnaire (in Supporting Information online) was sent to the 109 level III neonatal units in Italy to ascertain existing guidelines for total bilirubin monitoring and treatment of hyperbilirubinaemia in preterm infants and occurrence of kernicterus. Results: There was a 61% (67/109) response rate. Eighty‐five per cent of responding units had either written guidelines coming from different literature sources or locally developed. The monitoring of bilirubin varied greatly in timing before, during and after jaundice development. Phototherapy and exchange transfusion were given to 56.0 ± 21.0% and 0.2 ± 0.4% of admitted preterm infants in participating centres. Five cases of kernicterus in preterm infants and eleven cases in term infants were documented over the last 10 years. Conclusion: The management of hyperbilirubinaemia in preterm infants is not uniform in Italy and would benefit from shared national guidance together with establishment of a kernicterus registry to guide therapy.     

Urinary tract infections in infants: comparison between those with conjugated vs unconjugated hyperbilirubinaemia

AIMS: The aim was to investigate conjugated and unconjugated hyperbilirubinaemia in association with urinary tract infection (UTI) in young infants. METHODS: Fifty infants aged <3 mths who developed prolonged jaundice among 2128 infants with UTI from 1984 to 2004 were enrolled retrospectively. They were divided into conjugated (n=22) and unconjugated (n=28) hyperbilirubinaemia groups and the clinical variables between the two were compared. RESULTS: Compared with the unconjugated group, the conjugated hyperbilirubinaemia group had statistically significantly lower haemoglobin (1.57 vs 1.80 micromol/L), higher aspartate aminotransferase (96 vs 32.5 U/L) and alanine aminotransferase (81.5 vs 16 U/L), were older on admission (48.0 vs 32.5 days), had a longer duration of jaundice before treatment (43.5 vs 30 days) and a higher incidence of E. coli infections (19/22 vs 15/28). The direct/total bilirubin ratio was linearly correlated with duration of jaundice before treatment (p=0.004). The most significant cut-off value for the duration of jaundice vis-à-vis the type of jaundice was 38 days (p=0.007). Patients who on presentation had had jaundice for >44 days (p=0.007) were unlikely to have unconjugated hyperbilirubinaemia. CONCLUSIONS: Infants with UTI may present with unconjugated hyperbilirubinaemia in the early stage. After 6 weeks, it is always conjugated hyperbilirubinaemia and is frequently associated with anaemia, elevated hepatic aminotransferases and E. coli infections.     

Correlation of cord bilirubin levels with hyperbilirubinaemia in ABO incompatibility.

We studied 91 offspring of ABO incompatible preganacies and 30 controls resulting from O--O pregnancies to test whether cord bilirubin levels could be used to predict the severity of hyperbilirubinaemia in ABO incompatibility. Blood group, direct Coombs''s test, and serum bilirubin estimations were carried out on cord blood, and bilirubin estimations at 12, 24, 36, and 48 hours of life.     

Pathogenesis of oxytocin-induced neonatal hyperbilirubinaemia.

100 term (gestation at least 37 weeks), vertex presenting, vaginally delivered, and fetomaternal blood-group-compatible neonates were studied to evaluate the pathogenesis of neonatal hyperbilirubinaemia induced by oxytocin. 50 infants were born after oxytocin infusion for augmentation of labour and the other 50 were delivered spontaneously. The babies born after oxytocin induction of labour attained significantly higher serum bilirubin levels at age 72 +/- 12 hours than the controls. Infants born after oxytocin showed significant hyponatraemia, hypo-osmolality, and enhanced osmotic fragility of erythrocytes at birth. These biochemical and physiological alterations can be explained by the antidiuretic effects of oxytocin and concomitant administration of large quantities of electrolyte-free dextrose solutions used to administer it. Our observations suggest that cord serum sodium and/or osmolality should be estimated and infants with serum sodium less than 125 mmol/l and/or osmolality less than 260 mmol/kg should be considered for prophylactic administration of phenobarbitone.     

Serum malondialdehyde concentration in babies with hyperbilirubinaemia

AIM: To determine lipid peroxide concentrations in the first 10 days of life. METHODS: Malondialdehyde concentrations were investigated in neonates with or without hyperbilirubinaemia during the first 10 days of life. RESULTS: Serum malondialdehyde concentrations were higher in infants with hyperbilirubinaemia than in controls. A positive correlation was found between malondialdehyde and bilirubin concentrations in the study group. When the study group was categorised according to the presence of haemolysis, a significant correlation was found between malondialdehyde and bilirubin concentrations in those infants with hyperbilirubinaemia due to haemolysis. There was no such correlation in those without haemolysis. CONCLUSION: Exchange transfusion rapidly produces variable changes in pro-oxidant and antioxidant plasma concentrations in neonates, which may be responsible for free radical metabolism. The fall in malondialdehyde concentration is probably directly related to its exogenous removal by exchange transfusion.